1 / 41

Clin Med II Infectious Disease

Clin Med II Infectious Disease. Lecture II—Viral Diseases, part 3/3. Measles . Measles. Acute systemic paramyxovirus Inhalation of infective droplets Major worldwide cause of morbidity and mortality 750,000 deaths in 2000  197,000 deaths in 2007

lindsay
Download Presentation

Clin Med II Infectious Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clin Med II Infectious Disease Lecture II—Viral Diseases, part 3/3

  2. Measles

  3. Measles • Acute systemic paramyxovirus • Inhalation of infective droplets • Major worldwide cause of morbidity and mortality • 750,000 deaths in 2000  197,000 deaths in 2007 • Rising rates of intentional undervaccination—sporadic outbreaks • Highly contagious

  4. Measles • Fever (40-40.6 C or 104-105 F) • Malaise, coryza, cough, conjunctivitis • Koplik spots • Rash appears about 4 days after oonset • Pinhead-sized papules  brick-red, irregular, blochymaculopapular rash  may become uniform erythema • Face and behind ears  trunk  extremities • Erythematous pharynx with yellowish tonsillar exudate • Coated tongue • Generalized lymphadenopathy • Splenomegaly

  5. Measles

  6. Measles

  7. Measles • Labs—Leukopenia, thrombodytopenia, proteinuria • Can culture virus from nasopharyngeal washings and blood • IgM measles bodies or 4x rise in serum hemagglutination inhibition, fluorescent antibody staining of respiratory or urinary epithelial cells • Complications • CNS—postinfectious encephalomyelitis—multiple forms—read in text • Bronchopneumonia, bronchiolitis, bronchiectasis • Secondary bacterial infections • Immune reactivity • Gastroenteritis • Conjunctivitis, keratitis, otosclerosis

  8. Measles—Treatment • General—isolation until week following rash onset; bed rest until afebrile • Antipyretics and fluids • High dose vitamin A—maintains GI and respiratory mucosa • Treatment of secondary bacterial infections • Encephalitis—symptomatic treatment only

  9. Measles • Prevention—immunization (12-15 mo, 4-6 yrs) • Do not give in pregnancy or immunosuppression • Report all cases to public health. Refer in cases of HIV and pregnancy • Admit: • Meningitis, encephalitis, myelitis • Severe pneumonia • Diarrhea that compromises fluid balance

  10. Mumps

  11. Mumps • Spread by respiratory droplets • Children are most commonly affected • Incidence highest in spring • Incubation 14-21 days • Up to 1/3 of infection--asymptomatic

  12. Mumps • Parotid tenderness, swelling • Trismus • Glands usually normal within 1 wk • Fever and malaise • Meningitis • Orchitis—most common extrasalivary site in adults • Pancreatitis—most common cause of pancreatitis in children

  13. Mumps • Labs—mild leukopenia, amylasemia (from salivary glands), mild kidney function abnormalities • CSF—pleiocytosis, hypoglorrhachia • Diagnosis—usually characteristic clinical picture • Isolate of virus from swab of the duct of the parotid or other affected salivary gland • Can isolate virus from CSF early in aseptic meningitis • Nucleic acid amplification—more sensitive than viral culture but limited availability • Elevated IgM--diagnostic

  14. Mumps • Treatment—isolate till swelling subsides, bed rest till afebrile; symptomatic relief • Topical compresses • IVIG—can try for complicated disease but no consensus • Meningitis—symptomatic; manage cerebral edema, airway, vital functions • Epididymoorchitis—scrotal support, ice bags, pain relief • Pancreatitis—symptomatic, hydration • Usually lasts no longer than 2 weeks • Prevention—live virus vaccine; routine immunization • Often in combination with measles, rubella and VZV

  15. Rubella

  16. Rubella • Systemic disase—togavirus transmitted by inhalation of infective droplets • One attack usually confers permanent immunity • Difficult to distinguish from mono, measles, other viral illnesses—arthritis is more prominent in rubella • Principal importance—devastating effects on fetus in utero

  17. Rubella • Fetal—devastating • Postnatally acquired—innocuous—up to 50% asymptomatic • Fever, malaise, tender suboccipital adenitis, coryza • Arthritis—fingers, wrists, knees • Early posterior cervical and postauricular lymphadenopathy • Erythema of palate and throat • Fine pink maculopapular rash on face, trunk and extremities in rapid progression (2-3 days) and fades quickly1 day in each area

  18. Rubella

  19. Rubella • Labs—leukopenia • Diagnosis—elevated IgM antibody, isolation of virus, 4x or greater rise in IgG • False positive IgM—Epstein-Barr, CMV, parvovirus, RF • Exposure during pregnancy—immediate hemagglutination-binding rubella antibody level • Infection during 1st trimester—congenital rubella in 80% • Evaluate immunization—titers fall to seronegativity in 10% of patients after about 12 yrs

  20. Rubella • Congenital rubella—usually have wide variety of manifestations—eye disease, microphthatlmia, hearing deficits, psychomotor retardation, heart defects, organomegaly, maculopapular rash • Younger fetus at infection—more severe illness • Second trimester—deafness • Specific test for IgM rubella antibody • Postinfectious encephalopathy—mortality rate 20%

  21. Rubella • Treatment—symptomatic (acetaminophen) • Prognosis—mild—rarely lasts more than 3-4 days • Congenital—high mortality rate and permanent defects • Prevention—live attenuated rubella virus vaccine—often in combination with measles, mumps, and varicella • Try to immunize girls prior to menarche • Do not give immunization during pregnancy • In US—80% of 20-year-old women are immune to rubella

  22. Roseola

  23. Roseola • Human herpesvirus 6—principal cause of exanthema subitum • Primary HHV6—children under 2 years; major cause of infantile febrile seizures • May also see encephalitis and acute liver failure • HHV6 encephalitis—hippocampus, amygdala, limbus • Symptomatic HHV6 is rare in immunocompetent adults—mono-like illness (primary) or encephalitis (reactivated) • Can see infection during pregnancy / congenital transmission • Reactivated disease—mainly in immunocompromised adults—associated with graft rejection, graft-versus-host disease • May cause fulminant hepatic failure and acute decompensation of chronic liver disease in children

  24. Roseola

  25. Influenza

  26. Influenza • Highly contagious—respiratory droplets • 3 types of viruses—Type A infects many mammals and birds, Types B and C infect humans almost exclusively • Type A—subtypes from hemagglutinin (H) and neuraminidase (N) • Annual epidemics in fall and winter—10-20% of global population each year • Pandemics—longer intervals (decades)—major genetic reassortment of virus or mutation of animal virus • Main current viruses—H1N1 and H3N2 subtypes and type B.

  27. Influenza • Types A and B—clinically indistinguishable infections • Type C—minor • Abrupt onset—Fever, chills, malaise, myalgias, cough substernal soreness, headache, nasal stuffiness, nausea • Elderly—may present with only lassitude, confusion • Mild pharyngeal infection, flushed face, conjunctival redness, cervical lymphadenopathy • Labs—leukopenia, may see leukocytosis; proteinuria; isolate virus from throat swasbs, nasal washings, cell cultures • Rapid assays—nasal or throat swabs—60-80% sensitivity

  28. Influenza • Complications—necrosis of respiratory epithelium—secondary bacterial infections • Bacterial enzymes activate influenza viruses • Frequent complications—sinusitis, otitis media, purulent bronchitis, pneumonia • Young children, pregnant women, elderly, LTC facility patients, patients with comorbidities—higher risk of complications • Read—Reye Syndrome

  29. Influenza • Treatment—bed rest, analgesics, cough medicine • Treat - suggestive clinical infection or laboratory confirmed influenza and high risk for complications • No proven benefit of antivirals after 48 hrs, but should consider if patient is hospitalized • Neuraminidase inhibitors—inhaled zanamivir or oral oseltamivir—equally effective in treatment • reduce duration of symptoms and secondary complications • do not reduce hospitalizations or mortality • Adamantanes—amantadine and rimantadine—high levels of resistance and not recommended for treatment • Prognosis—uncomplicated lasts 1-7 days; excellent prognosis in healthy, nonelderly adults • Prevention—annual administration of influenza vaccine • Read—information on flu vaccine including contraindications

  30. HPV

  31. Human Papilloma Virus • Skin Warts—flat (superficial) or plantar (deep growths)—typically regress over time—HPV 1-4 • Benign Head and Neck Tumors— • single oral papillomas—pedunculated with stalk and rough papillary appearance • Laryngeal papillomas—most often caused by HPV-11—most common benign epithelial tumors of larynx; can cause airway obstruction in children • CondylomaAcuminata—almost exclusively on squamous epithelium of external genitalia and perianal areas • 90% due to HPV 6 and HPV 11

  32. Human Papilloma Virus—Skin Warts

  33. Human Papilloma Virus—Oral papilloma

  34. Human Papilloma Virus—CondylomaAcuminata

  35. Human Papilloma Virus—CondylomaAcuminata

  36. Human Papilloma Virus • Cervical dysplasia—koilocyotic cells—HPV 16-18 (70%) • Dysplasia—40-70% of lesions spontaneously regress • Progressive changes from mild (CIN I) to moderate (CIN II) to severe (CIN III) dysplasia, carcinoma in situ, or both

  37. HPV Diagnosis • wart can be confirmed microscopically by histologic appearance—hyperplasia of prickle cells and excess keratin • HPV infection—koilocytoctic (vaculolated) squamous epithelia cells that are rounded and occur in clumps • HPV virions on electron microscopy • Molecular probes for HPV DNA—establish in cervical swab and tissue • HPV does not gro in cell cultures • HPV antibodies—rarely used

  38. Human Papilloma Virus • Treatment—spontaneous disappearance of warts is the rule; may take months to years • Cryotherapy, Electrocautery, Chemical • Recurrences are common • See guidelines for follow-up on cervical dysplasia • Prevention—HPV quadrivalent vaccine (Gardasil) • Types 6,11,16,18

  39. HIV

  40. HIV Whole chapter of its own—I suggest you read!  You should know: • Major risk factors/Modes of transmission • Presenting symptoms (Hallmark of symptomatic HIV?) and major complications • Prevention measures • HIV risk for health care professionals • Major pathogens that need prophylaxis • Indications for antiretroviral therapy

  41. Questions?

More Related